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Background: With varied immunohistochemistry scoring criteria and patient cohorts, HER2-positivity rates in gastric
cancer (GC) and gastroesophageal junction (GEJ) adenocarcinoma have been reported with a wide range. Recently
standardized scoring criteria for GC and GEJ cancer has been established and recommended. In this study, the
frequency of HER2 expression and the relationship between HER2 expression and clinicopathological features were
examined in a large cohort of Chinese GC and GEJ cancer patients.
Methods: A total of 1463 patients, including 929 primary GCs and 534 primary GEJ adenocarcinomas, was
retrospectively analyzed for HER2 overexpression by immunohistochemistry (IHC). Fluorescence in situ hybridization
(FISH) analysis was used in 308 GCs and GEJ adenocarcinoma cases to assess HER2 gene amplification.
Results: HER2 overexpression (3+) was detected in 9.8% of carcinomas and more frequently observed in GEJ
cancer cases, in the intestinal type, and in the well or moderately differentiated type (P=0.003, 0.000, and 0.000,
respectively). HER2 equivocal (2+) was detected in 14.4% of cases. As for the 308 cases analyzed by FISH,
39 (of 40, 97.5%) IHC 3+ cases, 11 (of 38, 28.9%) IHC 2+ cases, and 3 (of 230, 1.3%) IHC 1+/0 cases showed HER2
gene amplification. A high concordance rate (98.5%) between IHC and FISH was demonstrated.
Conclusions: Approximately 10% of Chinese patients with primary GC and GEJ adenocarcinoma were
HER2-positive on IHC. HER2 overexpression was associated with GEJ site, intestinal cancer subtype, and well or
moderately differentiated carcinomas.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1935951199941072.
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Gastric cancer (GC) is the fourth most commonly diag-
nosed cancer and the second most common cause of
cancer-related deaths worldwide [1]. It has been sug-
gested that the incidence rate of gastroesophageal junc-
tion (GEJ) adenocarcinoma was increased in recent
years [2,3]. Despite some advances in the prevention and
treatment of gastric cancer, 5-year survival remains
around 20% in most parts of the world. HER2 is now well
recognized as a key factor in the development of certain* Correspondence: jmying@hotmail.com
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reproduction in any medium, provided the orsolid human tumors, most notably in breast cancer. HER2
gene amplification and protein overexpression, which
occur in 20% to 25% of breast cancer patients, have been
recognized as prognostic and predictive markers for
treatment [4]. Multiple detection methods have been
established to examine HER2 gene status and protein ex-
pression [5-8]. Trastuzumab, a recombinant monoclonal
antibody targeting HER2 protein, is now being applied not
only in metastatic breast cancer cases but also to localized
cases as adjuvant therapy [9,10]. A recent phase III ran-
domized study (ToGA) revealed that combination treat-
ment with trastuzumab and chemotherapy significantly
improved survival in patients with advanced GC or GEJ
cancer with HER2 overexpression [11]. Thus, trastuzumabd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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adenocarcinomas of the stomach and GEJ in many coun-
tries [12-17].
Although many studies have previously evaluated HER2
status in GC, the patient cohorts and scoring criteria have
varied, resulting in discrepancies in HER2-positivity rates
varying from about 4% to 53%, with a median rate of 18%
[18]. The ToGA study developed a new set of IHC scoring
criteria based on the study by Hofmann et al. [19] and
found HER2-positive (defined as IHC 3+ or IHC 2+/FISH+)
tumors in 16% of metastatic GC cases. The efficacy of
trastuzumab for treating metastatic GC with HER2
overexpression demonstrated in the ToGA study is also
promising for resectable HER2-positive gastric cancer. How-
ever, few studies have been conducted to examine the fre-
quency of HER2-positive tumors determined by the new
criteria in resectable gastric cancer [20,21], especially in a
large Chinese cohort. In this study, IHC analysis according
to standardized scoring criteria was used to assess the in-
cidence of HER2-positivity in primary resected GC and
GEJ cancer samples in a C9pt?>The relationship between
HER2 overexpression and gene amplification was also
examined in GC and GEJ adenocarcinoma.
Methods
Samples
A total of 1,463 patients with primary GC or GEJ adenocarcin-
oma, who received curative surgery (no history of neoadjuvant
chemotherapy) in the Cancer Institute & Hospital, Chinese
Academy of Medical Sciences (CICAMS), Beijing, China,
between August 2009 and February 2012, was included in
this retrospective study. All tumor samples were fixed in
10% neutral buffered formalin for 24–48 h and embedded
in paraffin, and routinely diagnosed in the Department of
Pathology, CICAMS, Beijing. The study protocol was ap-
proved by the Institutional Review Board (IRB). The pa-
tients’ medical records were reviewed to obtain patients’
clinicopathological parameters, including age at diagnosis,
sex, tumor location, histological classification, and patho-
logical TNM stage. Histological classification was deter-
mined according to the World Health Organization (WHO)
classification and Lauren’s classification.
Immunohistochemistry
Automated IHC was performed on 4-μm-thick sections
using an automated slide stainer, the Ventana Bench-
mark XT (Ventana Medical Systems, Tucson, AZ, USA),
according to the manufacturer’s instructions, for the
Ventana CONFIRM™ HER2/neu (4B5) Rabbit Monoclo-
nal Primary Antibody. HER2 IHC was scored using the
scoring scheme proposed by Hofmann et al. [19] in the
ToGA cohort of gastric cancer (ToGA score) and
Ruschoff et al. [22] as follows: 0, no staining or mem-
branous reactivity in <10% of tumor cells; 1+, faint/barely perceptible membranous reactivity in ≥10% of
tumor cells (cells are reactive only in part of their mem-
brane); 2+, weak to moderate complete, basolateral, or
lateral membranous reactivity in ≥10% of tumor cells;
and 3+, complete, basolateral, or lateral membranous re-
activity of strong intensity in ≥10% of tumor cells.
Samples scoring IHC 0 or IHC 1+ were considered
negative for HER2 overexpression, whereas samples scoring
IHC 3+ were considered positive for HER2 overexpression.
Samples scoring IHC 2+ were considered equivocal for
HER2 overexpression.
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) analysis was car-
ried out with the PathVysion HER2 DNA probe kit and
procedures (Vysis/Abbott, Abbott Park, IL, USA). The kit
contains two fluorochrome-labeled DNA probes, LSI HER2
(labeled with SpectrumOrange) and CEP17 (chromosome
17 enumeration probe, labeled with SpectrumGreen). Pre-
treatment was carried out with the Paraffin Pretreatment
Kit (VysisAbbott). The HER2 signals and CEP17 signals of
20 nuclei of invasive tumor cells in two different areas were
counted using a Zeiss AxioImager M2 epifluorescence
microscope (Carl Zeiss, Oberkochen, Germany) equipped
with an ×100 oil immersion objective and 4’,6’-diamidino-2-
phenylindole (DAPI)/Spectrum Green/Orange single and
triple bandpass filters. The HER2/chromosome 17 ratios
were interpreted as follows: a HER2/CEP17 ratio higher
than 2.2 was defined as amplification of the HER2 gene,
while a ratio <1.8 was defined as no amplification of the
HER2 gene. When the ratio was between 1.8 and 2.2, sig-
nals in another 20 nuclei were counted, and the HER2/
CEP17 ratio in a total of 40 nuclei was determined. When
the ratio was ≥2.0, it was defined as amplification of the
HER2 gene; otherwise it was defined as no amplification of
the HER2 gene.
Statistical analysis
Statistical analysis was performed using the chi-square
test to analyze associations between HER2 status and
clinicopathological parameters. A P value less than 0.05
was considered significant. Data were analyzed using
the SPSS statistical software program for Microsoft
Windows (SPSS Inc., Chicago, IL, USA).
Results
HER2 overexpression and clinicopathological
characteristics
A total of 1,463 patients was evaluated by IHC analysis.
The patients’ clinicopathological characteristics are listed
in Table 1. Their median age was 58 years (range, 20 to
82 years), with a male predominance (75.5%). Of all pa-
tients, there were 650 cases (44.4%) of intestinal type by
Lauren’s classification, 564 cases (38.6%) of diffused type,
Table 1 The correlation between HER2 expression status and clinicopathological parameters
Overall HER2 HER2- HER2-
Overexpression Equivocal Negative P value
Pathologic feature n=1463 n=143 (%) n=211 (%) n=1109 (%)
Age at diagnosis 0.102
≥60 years 683 80 (11.7) 108 (15.8) 495 (72.5)
<60 years 780 63 (8.1) 103 (13.2) 614 (78.7)
Sex 0.344
Male 1104 109 (9.9) 171 (15.5) 824 (74.6)
Female 359 34 (9.5) 40 (11.1) 285 (79.4)
Tumor location 0.003
GC 929 65 (7.0) 121 (13.0) 743 (80.0)
GEJ 534 78 (14.6) 90 (16.9) 366 (68.5)
Tumor subtype
(Lauren classification) 0.000
Intestinal 650 109 (16.8) 111 (17.1) 430 (66.2)
Diffuse 564 13 (2.3) 63 (11.2) 488 (86.5)
Mixed 249 21 (8.4) 37 (14.9) 191 (76.7)
Tumor differentiation 0.000
Well 25 4 (16) 9 (36) 12 (48)
Moderately 369 74 (20.1) 70 (19.0) 225 (61.0)
Poorly 1069 65 (6.1) 132 (12.3) 872 (81.6)
pT status 0.053
pT1 206 16 (7.8) 33 (16.0) 157 (76.2)
pT2 147 23 (15.6) 28 (19.0) 96 (65.3)
pT3 1074 102 (9.5) 145 (13.5) 827 (77.0)
pT4 36 2 (5.6) 5 (13.9) 29 (80.6)
pN status 0.074
pN0 411 39 (9.5) 66 (16.1) 306 (74.5)
pN1 235 27 (11.5) 42 (17.9) 166 (70.6)
pN2 306 20 (6.5) 42 (13.7) 244 (79.7)
pN3 511 57 (11.2) 61 (11.9) 393 (76.9)
pM status 0.571
pM0 1429 140 (9.8) 119 (8.3) 1080 (75.6)
pM1 34 3 (8.8) 2 (5.9) 29 (85.3)
pTNM stages 0.327
IA 162 14 (8.6) 29 (17.9) 119 (73.5)
IB 93 8 (8.6) 17 (18.3) 68 (73.1)
IIA 201 25 (12.4) 33 (16.4) 143 (71.1)
IIB 230 25 (10.9) 34 (14.8) 171 (74.3)
IIIA 264 15 (5.7) 37 (14.8) 212 (80.3)
IIIB 455 51 (11.2) 56 (12.3) 348 (76.5)
IIIC 24 2 (8.3) 3 (12.5) 19 (79.2)
IV 34 3 (8.8) 2 (5.9) 29 (85.3)
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location, approximately two-thirds of tumors were pri-
mary gastric cancers (63.5%), and one-third was primary
GEJ adenocarcinomas (36.5%). The tumors were poorly
differentiated in 73.1%, moderately differentiated in
25.2%, and well-differentiated in 1.7%. Overall, most pa-
tients were at pathologic stage T3 (73.4%), with 14.1%,
10%, and 2.5% at stage T1, T2, and T4, respectively.
Regarding the pathologic N stage, there was an approxi-
mately equal distribution of patients at N0, N1, N2, or
N3 stages (28.1%, 16.1%, 20.9%, 34.9%, respectively). The
majority of patients (97.7%) had no distant metastases.
Of the 1463 patients, 143 (9.8%) patients were scored as
HER2 overexpression (3+), while 211 (14.4%) and 1109
(1463, 75.8%) were equivocal and negative, respectively.
Table 1 summarizes HER2 expression status by subgroup.
HER2 was overexpressed (score 3+) in 7.0% (65/929) of
GC cases and 14.6% (78/534) of GEJ adenocarcinoma
cases (Figure 1A). Equivocal expression (2+) of HER2Figure 1 Representative cases of IHC staining and FISH analysis in GC
basolateral, or lateral membranous reactivity of strong intensity (3+) in tum
to moderate complete, basolateral, or lateral membranous reactivity (2+) in
membranous reactivity (1+) in tumor cells (original magnification, ×200). D
case with HER2 amplification using FISH analysis. Green signals refer to the
target probe for HER2. F. A GC case without HER2 amplification using FISHprotein was observed in 13.0% (121/929) of GC cases and
16.9% (90/534) of GEJ adenocarcinoma cases (Figure 1B).
HER2 was negative (1+/0) in 80.0% (743/929) of GC cases
and 68.5% (366/534) of GEJ adenocarcinoma samples
(Figure 1C and D). A significant difference in HER2 over-
expression was found between GCs and GEJ adenocar-
cinomas (7.0% vs. 14.6%, P<0.05). HER2 overexpression
was associated with the intestinal-type carcinomas by the
Lauren classification (P<0.001): 16.8% in intestinal vs. 2.3/
8.4% in diffuse-/mixed-type cancers. HER2 overexpression
was also correlated with well or moderately differentiated
carcinomas according to the WHO classification. No cor-
relation was observed between HER2 overexpressed and
not overexpressed cases in terms of age, sex, pT, N, M fac-
tors, or pathologic TNM stage.
Concordance of HER2 IHC and FISH
FISH analysis was performed in 308 randomly selected GC
and GEJ adenocarcinoma cases, including 40 cases withand GEJ adenocarcinoma. A. HER2 IHC staining shows complete,
or cells (original magnification, ×40). B. HER2 IHC staining shows weak
tumor cells (original magnification, ×100). C. faint/barely perceptible
. no staining (0) in tumor cells (original magnification, ×200). E. a GC
reference probe of Chr. 17 centromere, while red signals are the
analysis.
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(IHC 2+), and 230 cases with negative (IHC 1+/0) HER2
expression. HER2 amplification was observed in 97.5%
(39/40) of HER2 IHC 3+ cases, 28.9% (11/38) of HER2
IHC 2+ cases, and 1.3% (3/230) of HER2-negative (1+/0)
cases, showing a concordance rate of 98.5% between IHC
and FISH (Table 2) (Figure 1E and F).Discussion
In this study, 143 of 1463 (9.8%) of GC and GEJ adeno-
carcinoma cases were HER2-positive (3+) by IHC in one
of the largest Chinese studies to date. In the ToGA trial,
the percentage of HER2-positive (IHC 3+ or IHC 2+/FISH
positive) GC or GEJ cancer patients was 22.1% overall and
around 10.4% of IHC 3+ in resected samples [23], similar
to the present result. Recent studies also reported a range
of 8.5% to 10.3% for HER2 overexpression in GC
[20,21,24]. Recently, three studies in Chinese GC cases ap-
plied the same FDA-approved reagents and scoring cri-
teria and reported HER2 IHC 3+ rates of 9.0% (77/860)
[25], 6.9% (10/145) [26], and 5.8% (4/69) [27], respectively,
all slightly lower than the present result. This variation
may be partly explained by different sample sets. In
addition, HER2-positivity varied by tumor site, with higher
rates of HER2-positivity in GEJ adenocarcinoma than in
stomach cancer in this study (14.6% vs. 7.0% respectively;
P<0.01), which is consistent with the results of other stu-
dies [11,20]. In the ToGA trial, the countries with the highest
ratio of GEJ:stomach cancer were found to have above-
average HER2-positivity rates, regardless of sample size [23].
Another explanation is the different ratio of intestinal:diffuse/
mixed cancer among the studies. A positive association be-
tween HER2-positivity and intestinal-type cancers was identi-
fied in this and other studies [28-33]. In the ToGA trial, for
example, countries with higher ratios of intestinal:diffuse/
mixed cancer had increased HER2-positivity rates [23].
No correlation was found between HER2 overexpression
and pT, N, or M factors, or TNM stages, in the present
study. Previous studies including all pathological stages
have also reported no correlation between pathological
stage and overexpression [20,21,24]. A correlation of
HER2-positivity with well or moderately differentiated car-
cinomas was found in the present study (P<0.01). How-
ever, other studies demonstrated both an association andTable 2 Correlation between HER2 overexpression and




Amplification 39 (97.5%) 11 (28.9%) 3 (1.3%) 53
No amplification 1(2.5%) 27 (71.1%) 227 (98.7%) 255
Total 40 38 230 308no association between HER2 overexpression and tumor
differentiation [25,32,34,35]. These conflicting data may
be due to different sample sizes and the low prevalence
of HER2 in GC and GEJ adenocarcinoma. In addition,
varying methods of evaluation and scoring schemes with
different cut-points were used before the establishment
of a standard guideline for assessing HER2 expression.
Perhaps with the current consistent guidelines for HER2
assessment in this disease, future studies will provide
more clarity regarding this issue.
The present study revealed a high concordance rate,
98.5%, between IHC and FISH, which is similar to an-
other study of surgical resections from 145 Chinese GC
cases, with a concordance rate of 94.5% [26]. In contrast,
in the ToGA study, the concordance rate of IHC and
FISH was 87.2%, as 7.5% of IHC 1+/0 samples and 54.6%
of IHC 2+ cases were found to be FISH-positive [23].
One of the possible explanations for this discrepancy
might be different specimen types and reagents. In the
ToGA study, both biopsies and surgically-resected speci-
mens were included; the HER2-positivity rate was higher
in biopsies than in surgically-resected specimens (23.1%
vs. 19.9%; P=0.03), and biopsy samples were also more
likely to be HER2-amplified than surgical samples when
analyzed by FISH (P=0.01) than by IHC [23]. The major-
ity of current studies using a standard guideline for
HER2 expression assessment used biopsies and tissue
microarrays (TMAs), which were tested analogous to bi-
opsies, to interrogate HER status in GC. The concord-
ance rate of IHC and FISH in these studies varied from
88.6% to 97.7% [20,32,36]. A specific study evaluating
HER2 protein expression on whole-tissue sections and
TMAs was conducted, indicating a discrepancy in HER2
expression on whole-tissue sections from TMAs. For in-
stance, the proportion of IHC 2+ was 4.7% in whole-
tissue sections, whereas it was 8.6% in TMAs, which
might be partially explained by heterogeneous HER2 ex-
pression [33]. Another possibility, which was revealed by
a study aiming to validate the guideline for HER2-
expression assessment in GC, was different interpreta-
tions of staining of TMAs among observers, although a
uniform assessment guideline was followed [22]. There-
fore, reliable separation of IHC 1+/0 and IHC 2+ may be
difficult in biopsy samples, and FISH analysis should be
used for definitive classification.
In conclusion, a thorough analysis of 1463 Chinese
GC/GEJ cancer cases using FDA-approved reagents
showed HER2 overexpression in 9.8% of carcinomas,
with a strong preference for GEJ location, intestinal can-
cer subtype, and well or moderately differentiated carci-
nomas. Approximately 29% of IHC 2+ cases showed HER2
gene amplification, and there was a high concordance
rate (98.5%) between IHC and FISH in GC and GEJ
adenocarcinoma.
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